Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology (NASDAQ: PBYI) has announced the approval of inducement restricted stock unit awards for two new non-executive employees. The Compensation Committee of Puma's Board of Directors approved the grant of 7,250 shares of common stock on February 4, 2025, under the company's 2017 Employment Inducement Incentive Award Plan.
The restricted stock units will vest over three years, with one-third vesting on February 1, 2026 (first anniversary), and one-sixth vesting every six months thereafter, contingent on continued employment. These awards were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) ha annunciato l'approvazione di premi azionari riservati per due nuovi dipendenti non esecutivi. Il Comitato di Compensazione del Consiglio di Amministrazione di Puma ha approvato la concessione di 7.250 azioni ordinarie il 4 febbraio 2025, nell'ambito del Piano di Premi Incentivi per l'Occupazione del 2017 dell'azienda.
Le unità di azioni riservate verranno maturate in tre anni, con un terzo che matura il 1° febbraio 2026 (primo anniversario), e un sesto che matura ogni sei mesi successivamente, subordinato alla continua occupazione. Questi premi sono stati concessi come incentivi all'occupazione in conformità con la Regola di Listaggio Nasdaq 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) ha anunciado la aprobación de premios en unidades de acciones restringidas para dos nuevos empleados no ejecutivos. El Comité de Compensación de la Junta Directiva de Puma aprobó la concesión de 7,250 acciones ordinarias el 4 de febrero de 2025, según el Plan de Premios de Incentivo por Empleo de 2017 de la empresa.
Las unidades de acciones restringidas se adquirirán durante tres años, con un tercio adquiriéndose el 1 de febrero de 2026 (primer aniversario), y un sexto adquiriéndose cada seis meses a partir de entonces, condicionado a la continuación del empleo. Estos premios se otorgaron como incentivos de empleo en cumplimiento con la Regla de Listado de Nasdaq 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI)는 두 명의 새로운 비임원 직원에 대한 유도 제한 주식 보상 승인을 발표했습니다. Puma의 이사회 보상위원회는 2025년 2월 4일에 회사의 2017 고용 유도 인센티브 수여 계획에 따라 7,250주를 승인했습니다.
제한 주식 단위는 3년에 걸쳐 분할 지급되며, 첫 번째 기념일인 2026년 2월 1일에 3분의 1이 분할 지급되고, 그 이후 매 6개월마다 6분의 1이 분할 지급됩니다. 이는 지속적인 고용을 조건으로 합니다. 이 상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유도로 지급되었습니다.
Puma Biotechnology (NASDAQ: PBYI) a annoncé l'approbation de l'attribution d'unités d'actions restreintes incitatives pour deux nouveaux employés non exécutifs. Le Comité de Rémunération du Conseil d'Administration de Puma a approuvé l'octroi de 7 250 actions ordinaires le 4 février 2025, dans le cadre du Plan de Récompenses d'Incentive à l'Emploi de 2017 de l'entreprise.
Les unités d'actions restreintes deviendront acquises sur une période de trois ans, avec un tiers devenant acquis le 1er février 2026 (premier anniversaire), et un sixième devenant acquis tous les six mois par la suite, sous réserve de l'emploi continu. Ces récompenses ont été accordées comme incitations à l'emploi conformément à la Règle de Listage Nasdaq 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) hat die Genehmigung für die Vergabe von beschränkten Aktieneinheiten als Anreiz für zwei neue nicht-executive Mitarbeiter bekannt gegeben. Der Vergütungsausschuss des Vorstands von Puma genehmigte am 4. Februar 2025 die Zuteilung von 7.250 Stammaktien im Rahmen des Unternehmensplans für Anreizprämien zur Beschäftigung von 2017.
Die beschränkten Aktieneinheiten werden über drei Jahre hinweg fällig, wobei ein Drittel am 1. Februar 2026 (erster Jahrestag) fällig wird und danach alle sechs Monate ein Sechstel fällig wird, abhängig von der Fortsetzung der Beschäftigung. Diese Auszeichnungen wurden als Anreizzahlungen gemäß der Nasdaq-Listungsregel 5635(c)(4) gewährt.
- Company maintains ability to attract talent through equity compensation
- Potential dilution of existing shareholders through new stock awards
The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award’s vesting commencement date, February 1, 2025, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205589001/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Source: Puma Biotechnology, Inc.
FAQ
How many shares were granted in PBYI's February 2025 inducement awards?
What is the vesting schedule for PBYI's February 2025 inducement awards?
Under which plan were PBYI's February 2025 inducement awards granted?
What Nasdaq rule governs PBYI's February 2025 inducement awards?
